Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US
| Autor: | Hairong Huo, Stella Min, Amanda M Kong, Deepa S. Subramaniam, Melissa Pavilack, Rahul Shenolikar, Christina Chebili-Larson, Meghan Moynihan, Elizabeth Hoit Marchlewicz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Insurance Claim Review 03 medical and health sciences Egfr tki Sex Factors 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans In patient Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Aged biology Brain Neoplasms business.industry 030503 health policy & services Health Policy Age Factors Middle Aged medicine.disease respiratory tract diseases ErbB Receptors Models Economic Socioeconomic Factors Healthcare utilization 030220 oncology & carcinogenesis biology.protein Health Resources Non small cell Health Expenditures 0305 other medical science business |
| Zdroj: | Journal of Medical Economics. 24:328-338 |
| ISSN: | 1941-837X 1369-6998 |
| DOI: | 10.1080/13696998.2021.1885418 |
| Popis: | Non-small cell lung cancer (NSCLC) with brain metastases (BM) is difficult to treat and associated with poor survival. This study assessed the impact of BM on healthcare-related utilization and costs (HRUC) among patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).Adults newly-diagnosed with metastatic NSCLC, initiating first-/second-generation EGFR-TKI treatment, with BM or no BM (NBM), were identified retrospectively from IBM MarketScan healthcare claims databases (2013-2017). HRUC were measured during the variable-length follow-up period. Generalized linear models assessed the impact of BM on total healthcare costs, standardized to 2017 US$.Overall, 222 BM and 280 NBM patients were included, with a mean duration of follow-up of 14 months. Adjusted NSCLC-related and all-cause costs over average follow-up were 1.2 times higher among BM patients (Δ$5,640 and Δ$6,366, respectively;NSCLC-related HRUC, especially those attributable to radiation treatment, were higher among patients with BM. Future research should compare the potential for CNS-active EGFR-TKIs vs first-/second-generation EGFR-TKIs combined with radiotherapy to reduce HRUC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|